Longterm Safety and Efficacy of Adalimumab and Infliximab for Uveitis Associated with Juvenile Idiopathic Arthritis

• DOI: 10.3899/jrheum.171006
• Publication Date: 2018-04-15T11:35:13Z
• Authors: Vanessa Cecchin; Maria Elisabetta ...; Daniele Ferrari; Irene Pontikaki; Elisabetta Misero...; Maria P. Paroli; Claudia Bracaglia; Denise Pires Marafon; Serena Pastore; Fulvio Parentin; Gabriele Simonini; Cinzia De Libero; Fernanda Falcini; Antonella Petaccia; Giovanni Filocamo; Riccardo De Marco; Francesco La Torre; Silvana Guerriero; Silvana Martino; Francesco Comacchio; Valentina Muratore; Giorgia Martini; Fabio Vittadello; Francesco Zulian
• Keywords: Refractory (planetary science)

Anti-TNF-α agents have significantly changed the management of juvenile idiopathic arthritis (JIA). We evaluated safety and efficacy adalimumab (ADA) infliximab (IFX) for treatment JIA-associated uveitis in patients treated ≥ 2 years.Patients with IFX ADA were managed by a standardized protocol data entered ORCHIDEA registry. At baseline, all refractory to standard immunosuppressive or corticosteroid-dependent. Data recorded every 3 months course, number/type ocular flares complications, drug-related adverse events (AE), switch withdrawal. years analyzed descriptive statistics.Up December 2014, 154 24 followup included study. Fifty-nine 95 ADA. Clinical remission, defined as absence > 6 on treatment, was achieved 69 (44.8%), better remission rate (60.0%) compared (20.3%; p < 0.001). A significant reduction observed without difference between modalities. The number new complications decreased both groups but lower (p = 0.015). No serious AE recorded; 16.4% experienced 35 minor incidence than IFX.At 2-year followup, showed profile uveitis.